Compare Johnson & Johnson (JNJ) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Victoria's Secret & Co — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Victoria's Secret & Co trades at $82.87 (market cap $6.91B). The key difference: Johnson & Johnson is far larger — about 89.4× Victoria's Secret & Co's market cap, and Johnson & Johnson pays a 2.09% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Victoria's Secret & Co for 34 Days on average.
| JNJ | VSXY | |
|---|---|---|
Market Cap | $618.09B | $6.91B |
Volume | 6,050,983 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $99.97 |
52-Week Low | $186.00 | $28.25 |
Typical Hold Time | 129 Days | 34 Days |
Enterprise Value | $646.37B | $9.29B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Victoria's Secret (VSXY) trades at $86.61, up 0.96% with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with three consecutive earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy driving international growth.
The outlook appears positive with 60% analyst buy ratings and $86.80 consensus target, though rich valuation (P/E 19.33) and rising costs present risks. Key catalysts include sustained margin improvement and global expansion execution, while competition and demand volatility remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
